Evidence map›Paper›PMID 36425923›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Acute and Post-Acute COVID-19 Outcomes Among Immunologically Naïve Adults During Delta Versus Omicron Waves.

Margaret K Doll, Alpana Waghmare, Antje Heit, Brianna Levenson Shakoor, Louise E Kimball, Nina Ozbek, Rachel L Blazevic, Larry Mose, Jim Boonyaratanakornkit, Terry L Stevens-Ayers and 12 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Margaret K DollDepartment of Population Health Sciences, Albany College of Pharmacy & Health Sciences, Albany, NY, USA.
Alpana WaghmareDivision of Infectious Diseases, Department of Pediatrics, University of Washington, Seattle, WA, USA.
Antje HeitAmazon, Inc., Seattle, WA, USA.
Brianna Levenson ShakoorCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Louise E KimballVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Nina OzbekVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Rachel L BlazevicVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Larry MoseVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Jim BoonyaratanakornkitVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Terry L Stevens-AyersVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Kevin CornellSt. Luke's Medical Center, Ketchum, ID, USA.
Benjamin D SheppardSt. Luke's Medical Center, Ketchum, ID, USA.
Emma HampsonSt. Luke's Medical Center, Ketchum, ID, USA.
Faria SharminDepartment of Population Health Sciences, Albany College of Pharmacy & Health Sciences, Albany, NY, USA.
Benjamin GoodwinCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Jennifer M DanCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Tom ArchieSt. Luke's Medical Center, Ketchum, ID, USA.
Terry O'ConnorSt. Luke's Medical Center, Ketchum, ID, USA.
David HeckermanAmazon, Inc., Seattle, WA, USA.
Frank SchmitzAmazon, Inc., Seattle, WA, USA.
Michael BoeckhVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Shane CrottyCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.

Funding

T follicular helper (Tfh) CD4+ T cell, germinal center, and antibody response dysfunction in human recurrent tonsillitisU19AI142742 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Shane P Crotty · 2019 to 2026
$32.8M
UC San Diego RAPID Faculty Development Program in Infectious DiseasesR25AI147376 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ADRIANA H TREMOULET, Joann Trejo · 2020 to 2026
$2.5M
The Immunology of Recurrent Group A Streptococcus TonsillitisK08AI135078 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAN, JENNIFER MARIE · 2018 to 2022
$972k
NIAID NIH HHS K08 AI135078NIAID NIH HHS R25 AI147376NIAID NIH HHS U19 AI142742
6 · The paper itself

Abstract

Importance: The U.S. arrival of the Omicron variant led to a rapid increase in SARS-CoV-2 infections. While numerous studies report characteristics of Omicron infections among vaccinated individuals and/or persons with a prior history of infection, comprehensive data describing infections among immunologically naïve adults is lacking. Objective: To examine COVID-19 acute and post-acute clinical outcomes among a well-characterized cohort of unvaccinated and previously uninfected adults who contracted SARS-CoV-2 during the Omicron (BA.1/BA.2) surge, and to compare outcomes with infections that occurred during the Delta wave. Design: A prospective cohort undergoing high-resolution symptom and virologic monitoring between June 2021 and September 2022. Setting: Multisite recruitment of community-dwelling adults in 8 U.S. states. Participants: Healthy, unvaccinated adults between 30 to 64 years of age without an immunological history of SARS-CoV-2 who were at high-risk of infection were recruited. Participants were followed for up to 48 weeks, submitting regular COVID-19 symptom surveys and nasal swabs for SARS-CoV-2 PCR testing. Exposures: Omicron (BA.1/BA.2 lineages) versus Delta SARS-CoV-2 infection, defined as a positive PCR that occurred during a period when the variant represented ≥50% of circulating SARS-CoV-2 variants in the participant's geographic region. Main Outcomes and Measures: The main outcomes examined were the prevalence and severity of acute (≤28 days post-onset) and post-acute (≥5 weeks post-onset) symptoms. Results: Among 274 immunologically naïve participants, 166 (61%) contracted SARS-CoV-2. Of these, 137 (83%) and 29 (17%) infections occurred during the Omicron- and Delta-predominant periods, respectively. Asymptomatic infections occurred among 6.7% (95% CI: 3.1%, 12.3%) of Omicron cases and 0.0% (95% CI: 0.0%, 11.9%) of Delta cases. Healthcare utilization among Omicron cases was 79% (95% CI: 43%, 92%, Conclusions and Relevance: These findings suggest that among previously immunologically naïve adults, few Omicron (BA.1/BA.2) and Delta infections are asymptomatic, and relative to Delta, Omicron infections were less likely to seek healthcare and experience post-acute symptoms.

Identifiers

PMID36425923
PMCPMC9685683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.